CytomX Therapeutics (CTMX) Projected to Post Quarterly Earnings on Thursday

CytomX Therapeutics (NASDAQ:CTMX) will likely be posting its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to post earnings of ($0.09) per share and revenue of $10.38 million for the quarter. Individuals may review the information on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 5:00 PM ET.

CytomX Therapeutics (NASDAQ:CTMX) last released its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.01). CytomX Therapeutics had a negative return on equity of 38.46% and a negative net margin of 435.21%. The business had revenue of $1.42 million during the quarter, compared to analysts’ expectations of $12.39 million. On average, analysts expect CytomX Therapeutics to post ($0.40) EPS for the current fiscal year and ($0.52) EPS for the next fiscal year.

CytomX Therapeutics Stock Performance

CytomX Therapeutics stock opened at $2.27 on Tuesday. The company has a market cap of $493.54 million, a P/E ratio of -4.53 and a beta of 2.21. CytomX Therapeutics has a one year low of $2.14 and a one year high of $8.21. The business has a fifty day moving average of $2.81 and a two-hundred day moving average of $3.86.

Analyst Upgrades and Downgrades

Several analysts recently commented on CTMX shares. Weiss Ratings reiterated a “sell (d)” rating on shares of CytomX Therapeutics in a research note on Friday, September 11th. Guggenheim decreased their price objective on shares of CytomX Therapeutics from $15.00 to $14.00 and set a “buy” rating on the stock in a report on Monday, August 10th. Wall Street Zen lowered shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, August 23rd. Zacks Research lowered shares of CytomX Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 19th. Finally, JPMorgan Chase & Co. dropped their target price on shares of CytomX Therapeutics from $12.00 to $11.00 and set an “overweight” rating for the company in a report on Thursday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.90.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing cancer medicines designed to be activated selectively within the tumor microenvironment. The company’s approach is intended to improve the precision of treatment by limiting activity in healthy tissues while enabling therapeutic effects at tumor sites.

CytomX’s research is based on its Probody therapeutic platform, which uses molecular masking and tumor-associated protease activity to conditionally activate antibody-based medicines.